Evidence map›Paper›PMID 41616002›Full record

ArticlePloS one2026

A deep state-space analysis framework for cancer patient latent state estimation and classification from EHR time-series data.

Yuji Okamoto, Aya Nakamura, Ryosuke Kojima, Eiichiro Uchino, Yohei Mineharu, Yohei Harada, Mayumi Kamada, Minoru Sakuragi, Manabu Muto, Motoko Yanagita and 1 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuji OkamotoDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Aya NakamuraDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ryosuke KojimaDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0003-1095-8864
Eiichiro UchinoDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yohei MineharuDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-6346-3999
Yohei HaradaDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Mayumi KamadaDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Minoru SakuragiDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Manabu MutoDepartment of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Motoko YanagitaDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yasushi OkunoDepartment of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0003-3596-4208

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advancements in deep learning technologies and an increase in medical data have enhanced the accuracy of disease diagnosis and treatment strategies. Notably, significant progress has been made in the use of deep learning-based time-series prediction models for short-term disease onset prediction and analysis of important features. However, research on explainable deep learning for long-term disease progression, such as cancer and chronic diseases, still faces challenges. The difficulty in estimating explainable gradual disease progression from observable patient test data is a key factor. To address this issue, we propose a new approach called the "deep state-space analysis framework." This framework utilizes sequentially obtained electronic health records (EHRs) to estimate and visualize temporal changes in the latent states of patients related to disease progression. It enables the clustering of latent patient states according to the severity of disease progression and identifies key factors leading to a poor prognosis with medication. To validate our framework, a detailed analysis of data from 12,695 patients with cancer was conducted. The estimated transitions of the latent states capture the clinical status of the patients and their continuous temporal changes. Furthermore, anemia was identified as a poor prognostic factor during state transitions in patients with cancer. Significant features were also confirmed, such as immune cell abnormalities, which are poor prognostic factors in patients treated with Nivolumab, Osimertinib, and Afatinib. This technological innovation deepens our understanding of disease progression and supports early treatment adjustments, prognostic evaluations, and the formulation of optimal long-term strategies. With the advancements in deep learning, its application in healthcare has even greater potential.

Indexed as

Deep LearningElectronic Health RecordsNeoplasmsData AnalyticsDisease ProgressionHumansPredictive Learning ModelsPrognosis

Identifiers

PMID41616002
PMCPMC12858016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.